Qualigen regains Nasdaq compliance with $4.5 million private placement

Published 28/07/2025, 22:30
Qualigen regains Nasdaq compliance with $4.5 million private placement

CARLSBAD, Calif. - Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage biotechnology company with a current market capitalization of $4.42 million, has regained compliance with Nasdaq’s minimum stockholders’ equity requirement through a $4.5 million private placement of Series A-3 Preferred Stock, the company announced Monday. According to InvestingPro data, the stock has declined over 33% year-to-date, reflecting ongoing challenges.

The company had received notice from Nasdaq on July 23 that it failed to meet the $2.5 million stockholders’ equity requirement under Nasdaq Rule 5550(b)(1), as reflected in its quarterly report for the period ended March 31, 2025.

In a separate communication on June 24, Nasdaq’s Office of General Counsel had accepted Qualigen’s request for an extension on three compliance items. The company has now fulfilled these requirements by filing its delayed quarterly report by the July 21 deadline, raising sufficient capital to meet the equity requirement by July 28, and submitting a plan to maintain compliance with listing standards over the next 12 months.

Qualigen intends to file a Current Report on Form 8-K with the Securities and Exchange Commission that will include a pro forma balance sheet demonstrating compliance with stockholders’ equity requirements.

The biotechnology firm, which focuses on developing treatments for cancer and infectious diseases, stated it is "making every effort" to maintain its Nasdaq listing but noted there is no guarantee it will be able to maintain compliance with continued listing requirements.

Qualigen’s announcement was based on a company press release statement.

In other recent news, Qualigen Therapeutics announced it has secured patents for its cancer drug QN-302 across 25 countries, including Europe, India, China, and Russia. These patents, titled "Substituted Naphthalene Diimides and Their Use," protect the product and its manufacturing methods, with coverage extending into 2040. Additionally, Qualigen Therapeutics has appointed Robert B. Lim as the new Chair of its Audit Committee. Mr. Lim, recognized as an “audit committee financial expert,” replaces Graydon Bensler, who will remain a member of the Board and the Audit Committee. However, the company is facing a potential Nasdaq delisting due to a failure to timely file its Quarterly Report for the period ended March 31, 2025. This delay is considered a violation of Nasdaq Listing Rule 5250(c)(1), and a hearing is scheduled where Qualigen will present its compliance plan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.